ECM
FOLD

Endurant Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Endurant Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-261,000
Closed -$3.94M – 80
2017
Q3 		$3.94M Buy
+261,000
New +$3.45M 1.19% 28

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Endurant Capital Management's FOLD Position: Q1 2019 in Review

Endurant Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 58,240 shares — an estimated $558K sold.

Endurant Capital Management first reported a position in FOLD in Q3 2016 and held it in 9 quarters. The position peaked at $2.97M in Q4 2017. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

  • Endurant Capital Management reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Endurant Capital Management sold 58,240 Amicus Therapeutics shares in Q1 2019, an estimated $558K.
  • Endurant Capital Management first reported a position in Amicus Therapeutics in Q3 2016 and held it in 9 quarters.
  • Endurant Capital Management's Amicus Therapeutics position peaked at $2.97M in Q4 2017.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.